Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1638 1647 1759
This examiner grants 41% of resolved cases
Allison Marie Johnson works in Tech Center 1700 and Art Unit 1638. With 44 resolved cases, the examiner maintains an allowance rate of 40.9 percent. This indicates a competitive prosecution environment where fewer than half of the applications are allowed. Practitioners should be prepared for rigorous scrutiny and may need to rely on multiple rounds of amendments to reach a favorable outcome.
The interview lift is 53.3 percent. This is a very high figure, especially when compared to the 40.9 percent allowance rate. It suggests that personal interaction is highly effective and may be one of the most important factors in overcoming rejections. An interview can clarify technical misunderstandings and help align the applicant's claims with the examiner's perspective, significantly improving the 40.9 percent baseline odds.
The median days to allowance is 1562. This duration reflects a long prosecution period, requiring patience and persistence from applicants. To navigate the 1562 day timeline successfully, practitioners should leverage the 53.3 percent interview lift early in the cycle. This strategy may help move the application toward the 40.9 percent allowance threshold more efficiently than written responses alone.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18884901 | SITE-SPECIFIC INTEGRATING RECOMBINANT AAV VECTORS FOR GENE THERAPY AND IMPROVED PRODUCTION METHODS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18211692 | REPLICATION-COMPETENT VESICULAR STOMATITIS VIRUSES | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17051089 | De Novo Formation of the Biliary System by Hepatocyte Transdifferentiation | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18858608 | METHODS AND COMPOSITIONS FOR PRODUCING MICROGLIA | Non-Final OA | President and Fellows of Harvard College |
| 17620650 | METHODS OF PROMOTING VASCULOGENESIS | Non-Final OA | BioTissue Holdings Inc. |
| 17624347 | PRIMING MEDIA AND METHODS FOR STEM CELL CULTURE AND THERAPY | Non-Final OA | Case Western Reserve University |
| 18939509 | COSMETIC COMPOSITION FOR ANTI-AGING OR WRINKLE REDUCTION COMPRISING CULTURE BROTH OF NEURAL STEM CELLS AS ACTIVE INGREDIENT AND METHOD OF PREPARING SAME | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | Final Rejection | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 17796334 | DNA Amplification Method | Final Rejection | Oxford University Innovation Limited |
| 18837469 | EXPRESSION SYSTEMS FOR THE ALPHA6-CONTAINING NICOTINIC ACETYLCHOLINE RECEPTOR AND METHODS OF USE THEREOF | Non-Final OA | Janssen Pharmaceutica NV |
| 17840310 | METHODS FOR TREATING PAIN | Non-Final OA | Duke University |
| 17326884 | RECOMBINANT VIRAL VECTORS AND NUCLEIC ACIDS FOR PRODUCING THE SAME | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18623529 | METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy